In today’s briefing:
- Xpeng (9868.HK, XPEV): Painful Year, but Payoffs for Technology Improvements Ahead
- Asia HY Monthly – October 2022 – Lucror Analytics
- Giant Biogene IPO Trading – Demand Was Relatively Better but Still Weak
Xpeng (9868.HK, XPEV): Painful Year, but Payoffs for Technology Improvements Ahead
- After a 86% decline on share price YTD, we believe it’s time to revisit Xpeng.
- Having gone through all the negatives which led to Xpeng’s underperforming vs peers, we believe the market has overreacted, while the company’s advantages/technology improvements have been ignored.
- After 4 months of sales decline, company fundamentals would bottom out from November onwards with G9 starting to speak for itself.
Asia HY Monthly – October 2022 – Lucror Analytics
The Asia Monthly focuses on providing updates on recent events, information on new issues and spread movements, as well as summarising our top picks. The Asia Monthly is intended to broaden investors’ understanding of the Asian USD high-yield market.
Giant Biogene IPO Trading – Demand Was Relatively Better but Still Weak
- Giant Biogene (GB) raised around US$70m by pricing its HK IPO at the low-end.
- GB is a leader in the bioactive ingredient-based professional skin treatment product industry in China.
- We had looked at various aspects of the deal in our previous note. In this note, we will talk about the demand for the deal and other trading dynamics.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
